Skip to main content



Invest in Sensore

Invest in Sensore

Sensore: a paradigm shift from reactive to proactive care, revolutionising the £3.7bn pressure ulcer prevention market.

A patented medical device platform designed to reduce one of healthcare’s most costly and preventable conditions, now in paid pilots with UK care providers.

Raising £1.1m (EIS Approved) to scale-up manufacture, launch Sensore S1 in early 2027 and develop Sensore M1 for launch in late 2027.

Sensore: a paradigm shift from reactive to proactive care, revolutionising the £3.7bn pressure ulcer prevention market.

A patented medical device platform designed to reduce one of healthcare’s most costly and preventable conditions, now in paid pilots with UK care providers.

Raising £1.1m (EIS Approved) to scale-up manufacture, launch Sensore S1 in early 2027 and develop Sensore M1 for launch in late 2027.

View the intro deck

View the intro deck

A wheelchair with the Sensore mat fitted to the seat, showing a blue pressure pattern

Where Sensore stands today.

device pilots

Source: [PLACEHOLDER: add citation]

device pilots

Source: [PLACEHOLDER: add citation]

on the waitlist

Source: [PLACEHOLDER: add citation]

on the waitlist

Source: [PLACEHOLDER: add citation]

seed raise

Source: [PLACEHOLDER: add citation]

seed raise

Source: [PLACEHOLDER: add citation]

committed

Source: [PLACEHOLDER: add citation]

committed

Source: [PLACEHOLDER: add citation]

medical device (pre-UKCA)

Source: [PLACEHOLDER: add citation]

medical device (pre-UKCA)

Source: [PLACEHOLDER: add citation]

Patent Granted

Core sensor technology protected by granted patent GB2602155.

Core sensor technology protected by granted patent GB2602155.

Paid Pilots

Paid pilots with UK national care home & domiciliary care groups validates clinical need, willingness to pay and real-world integration.

Regulatory Pathway

A clear UK, EU & FDA regulatory pathway established, with expert support from London Institute for Healthcare Engineering.

A clear UK, EU & FDA regulatory pathway established, with expert support from London Institute for Healthcare Engineering.

Key New Hires

Strategic hires across clinical, regulatory and commercial leadership strengthen execution capability.

2026: Certification
2027: Scale

2026: Certification
2027: Scale

These milestones put Sensore in a strong position to scale in 2026, focused on delivering our funded clinical usability study, preparing UKCA submission and converting early pilots, towards a planned launch in 2027.

Usability StudyNIHR FundedGlobal Patent FilingProcess Patent IdentifiedUser Co-Design60+ Device PilotsUKCA CertificationClass I Medical DeviceLaunchEarly 2027Sensore ProPersonal AI Model
Usability StudyNIHR FundedGlobal Patent FilingUK, EU, USA Process Patent IdentifiedUser Co-Design60+ Device PilotsUKCA CertificationClass I Medical DeviceLaunchEarly 2027Sensore ProPersonal AI Model

Why Invest Now?

Sensore has validated the problem, technology and early market demand, and is now capitalising on regulatory and market tailwinds to reach commercial scale.

Execution Phase

Core technology is patented and validated, deployed in operational care settings and integrating into real workflows.

This raise funds execution and scale, not product proof.

Persistent, High-Cost Problem

Commercial Validation

Defined Regulatory Pathway

Near-Term Value Inflection

Timing Is Right

View the pitch deck

Why Invest Now?

Sensore has validated the problem, technology and early market demand, and is now capitalising on regulatory and market tailwinds to reach commercial scale.

Execution Phase

Core technology is patented and validated, deployed in operational care settings and integrating into real workflows.

This raise funds execution and scale, not product proof.

Persistent, High-Cost Problem

Commercial Validation

Defined Regulatory Pathway

Near-Term Value Inflection

Timing Is Right

View the pitch deck

supported by

  • Innovate UK
    SFC Capital
    NHS Wales clinical innovation partner
    National Institute for Health and Care Research
    London Institute for Healthcare Engineering
    MSE Innovation
    UK Startup Awards
    Hello Tomorrow Deep Tech Pioneers
    Conception X
    TechBio Boost

Start the conversation.

We are engaging with aligned EIS investors to anchor our seed round, and welcome direct conversations and warm introductions. Our CEO will be in touch shortly.

Invest in Sensore

From reactive to proactive care.

A patented medical device platform designed to reduce one of healthcare’s most costly and preventable conditions, now in paid pilots with UK care providers, addressing the £3.7bn pressure ulcer prevention market.